RxDoctor Payments DataLook up a doctor →

Myriam Allende-Vigo, MD

Endocrinology, Diabetes & Metabolism · Humacao, PRNPI 1073517355

Payments from drug & device makers

$963,407in general payments, 2019–2025

Across 181 payments — averaging $5322.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$503K
  • Eli Lilly Export S.A. Puerto Rico Branch$451K
  • Eli Lilly$3K
  • Novo Nordisk$1K
  • Sanofi-aventis U.S. LLC$1K
  • AstraZeneca$628
  • plus $3K from 16 others
$7,136in research payments, 2019–2025

Across 1 payment — averaging $7135.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

What the payments were for

  • Consulting fees$5,75047%
  • Food & beverage$6,47853%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$963,407 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,050
Medicare patients
27
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide429$422,282
TrulicityDulaglutide341$353,160
JardianceEmpagliflozin474$326,022
OmnitropeSomatropin45$199,713
SynjardyEmpagliflozin/Metformin Hcl262$171,937
RybelsusSemaglutide115$121,817
FarxigaDapagliflozin Propanediol160$102,923
SynthroidLevothyroxine Sodium1,239$79,710
JanumetSitagliptin Phos/Metformin Hcl96$64,873
MounjaroTirzepatide56$61,796
JanuviaSitagliptin Phosphate86$61,348
Soliqua 100-33Insulin Glargine/Lixisenatide52$47,239
Synjardy XrEmpagliflozin/Metformin Hcl66$44,658
LantusInsulin Glargine,hum.Rec.Anlog432$35,092
Janumet XrSitagliptin Phos/Metformin Hcl61$35,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Jentadueto$541$549,564815 claims
Novo NordiskOzempic, Rybelsus, Novolog$1,137$548,936576 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Humulin N$149$458,864745 claims
MerckJanumet, Januvia, Janumet Xr$349$161,245243 claims
AstraZenecaFarxiga$628$102,923160 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$1,098$82,331484 claims
AbbVieSynthroid$502,943$79,7101,239 claims
Johnson & JohnsonXarelto, Invokana$392$26,89541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →